Welcome to ULS!
Welcome to ULS!
> Products > Inhibitors & Agonists > GPCR/G Protein > CGRP Receptor

MK-3207

Cat. No. :YN320225

  • CAS No. :957118-49-9

    • Pack size

      price

      inventory

    • 5mg

      Enquiry

      Enquiry

    • 10mg

      Enquiry

      Enquiry

    • 25mg

      Enquiry

      Enquiry

    • 50mg

      Enquiry

      Enquiry

    • Products Infomation
    • Biological Activity
    • Reference
    • Product Name:MK-3207
      CAS NO.:957118-49-9
      Chemical Name:
      Synonyms:
      Molecular Weight:557.59
      Molecular Formula:C₃₁H₂₉F₂N₅O₃
      SMILES:O=C1C2(NC[C@@H](C3=CC(F)=CC(F)=C3)N1CC(NC4=CC5=C(C[C@@]6(C(NC7=C6C=CC=N7)=O)C5)C=C4)=O)CCCC2
      Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
      Transportation:Room temperature in continental US; may vary elsewhere.
      Select Batch:
      Purity:
    • Description:MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12nM; Ki value= 0.024nM); highly selective versus human AM1, AM2, CTR, and AMY3. In common with other CGRP receptor antagonists, MK-3207 displays lower affinity for human CGRP receptors from other species, including canine and rodent. in vitro: MK-3207 is a potent antagonist of the human and rhesus monkey CGRP receptors (K(i) = 0.024nM). in vivo: MK-3207 produced a concentration-dependent inhibition of dermal vasodilation, with plasma concentrations of 0.8 and 7nM required to block 50 and 90% of the blood flow increase, respectively. The tritiated analog [3H]MK-3207 was used to study the binding characteristics on the human CGRP receptor. [3H]MK-3207 displayed reversible and saturable binding (K(D) = 0.06nM), and the off-rate was determined to be 0.012 min(-1), with a t(1/2) value of 59 min . After the first interim analysis, the two lowest MK-3207 doses (2.5, 5 mg) were identified as showing insufficient efficacy. Per the pre-specified adaptive design decision rule, only the 2.5-mg group was discontinued and the five highest doses (5, 10, 20, 50, 100 mg) were continued into the second stage . Clinical trial: MK-3207 for the treatment of acute migraines. Phase 2b
      IC50&Target:
      In Vitro:
      In Vivo:
      Clinical Trial:
      Solvent & Solubility:
      References:
    •  Molarity Calculator
    • Dilution Calculator
    Molar concentration calculator equation :
    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Calculation

    quality concentration volume Molecular weight
    Dilution calculator :
    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
    • C1
      V1
      C2
      V2


      Contact

      TELL : +86-020-82000279

      Email: sales@ubiochem.com

      Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.

    ULS products are chemical reagents for Research Use Only!Copyright © 2020-2021 ULS. All Rights Reserved.备案号:粤ICP备2021013238号-2
    6.344345s